IL162201A0 - New methods for diagnosis and treatment of tumours - Google Patents

New methods for diagnosis and treatment of tumours

Info

Publication number
IL162201A0
IL162201A0 IL16220103A IL16220103A IL162201A0 IL 162201 A0 IL162201 A0 IL 162201A0 IL 16220103 A IL16220103 A IL 16220103A IL 16220103 A IL16220103 A IL 16220103A IL 162201 A0 IL162201 A0 IL 162201A0
Authority
IL
Israel
Prior art keywords
tumours
diagnosis
treatment
new methods
new
Prior art date
Application number
IL16220103A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL162201A0 publication Critical patent/IL162201A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL16220103A 2002-01-03 2003-01-02 New methods for diagnosis and treatment of tumours IL162201A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (fr) 2002-01-03 2003-01-02 Nouvelles methodes de diagnostic et de traitement de tumeurs

Publications (1)

Publication Number Publication Date
IL162201A0 true IL162201A0 (en) 2005-11-20

Family

ID=26077560

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16220103A IL162201A0 (en) 2002-01-03 2003-01-02 New methods for diagnosis and treatment of tumours
IL162201A IL162201A (en) 2002-01-03 2004-05-27 Radio-isotope conjugated compounds, pharmaceutical compositions comprising them, uses thereof and method of production thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162201A IL162201A (en) 2002-01-03 2004-05-27 Radio-isotope conjugated compounds, pharmaceutical compositions comprising them, uses thereof and method of production thereof

Country Status (15)

Country Link
US (1) US20040001790A1 (fr)
EP (2) EP1461360B1 (fr)
JP (2) JP2005523887A (fr)
CN (1) CN1612895B (fr)
AU (1) AU2003210149B2 (fr)
BR (1) BR0306715A (fr)
CA (1) CA2468081A1 (fr)
CY (1) CY1110923T1 (fr)
HK (1) HK1076474A1 (fr)
IL (2) IL162201A0 (fr)
MX (1) MXPA04006517A (fr)
NO (1) NO20043246L (fr)
PL (1) PL369371A1 (fr)
RU (1) RU2352582C2 (fr)
WO (1) WO2003055917A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
EP1259548A1 (fr) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese
WO2002020563A2 (fr) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft RECEPTEUR DU DOMAINE DE LA EDb-FIBRONECTINE
US8491906B2 (en) 2002-03-11 2013-07-23 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
EP1514561A1 (fr) * 2003-09-10 2005-03-16 Philogen S.p.A. Ciblage de la vasculature tumorale avec l'utilisation de l'anticorps radio-marqué L19 contre le fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
EP1619501B1 (fr) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Utilisation des colorants cyanines dans le diagnostic des maladies associées à l'angiogénèse
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
WO2007128557A1 (fr) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr
CN101687923B (zh) * 2007-04-02 2013-06-19 菲洛根股份公司 与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原
EP2036576A1 (fr) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Fibronectine ED-B en tant que marqueur de stratification pour médicaments anti-tumeurs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (fr) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Utilisation d'une molécule radiomarquée se liant spécifiquement à la fibronectine ED-B dans un procédé de traitement du lymphome Hodgkin
EP2456472B1 (fr) 2009-07-22 2024-03-27 Actinium Pharmaceuticals, Inc. Procédés de génération de radioimmunoconjugués
JP5892540B2 (ja) * 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
WO2011110490A1 (fr) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Procédé pour la production de fragments d'anticorps scfv marqués radioactivement, kits et compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
WO2018073680A1 (fr) * 2016-10-17 2018-04-26 Pfizer Inc. Anticorps anti-edb et conjugués anticorps-médicament
AU2021276573B2 (en) * 2020-05-22 2023-12-21 Philogen S.P.A. Tnfalpha immunoconjugate therapy for the treatment of brain tumors
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Transgenic T cell receptors attached to antibody binding sites
WO2023196996A2 (fr) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Récepteur multipartite et complexes de signalisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125854T3 (es) * 1989-08-09 1999-03-16 Rhomed Inc Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
EP0625200B1 (fr) * 1992-02-06 2005-05-11 Chiron Corporation Proteine de liaison biosynthetique pour marqueur de cancer
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
EP1259548A1 (fr) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese

Also Published As

Publication number Publication date
RU2352582C2 (ru) 2009-04-20
AU2003210149A1 (en) 2003-07-15
CY1110923T1 (el) 2015-06-10
MXPA04006517A (es) 2005-03-31
JP4663020B2 (ja) 2011-03-30
US20040001790A1 (en) 2004-01-01
WO2003055917A2 (fr) 2003-07-10
PL369371A1 (en) 2005-04-18
JP2009209149A (ja) 2009-09-17
RU2004123785A (ru) 2005-08-10
JP2005523887A (ja) 2005-08-11
CN1612895B (zh) 2010-05-12
EP1461360B1 (fr) 2010-08-18
IL162201A (en) 2011-04-28
CA2468081A1 (fr) 2003-07-10
HK1076474A1 (en) 2006-01-20
NO20043246L (no) 2004-08-02
EP1461360A2 (fr) 2004-09-29
WO2003055917A3 (fr) 2003-12-24
BR0306715A (pt) 2004-12-28
AU2003210149B2 (en) 2008-10-09
CN1612895A (zh) 2005-05-04
EP2239274A1 (fr) 2010-10-13

Similar Documents

Publication Publication Date Title
IL162201A0 (en) New methods for diagnosis and treatment of tumours
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EP1551990A4 (fr) Diagnostic et traitement de tumeurs chimio-resistantes
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
WO2004030615A8 (fr) Compositions et procedes de diagnostic et de traitement de tumeur
WO2004016225A8 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
EP1811844A4 (fr) Méthodes de diagnostic et de traitement du cancer
EP1641378A4 (fr) Methodes et dispositifs de traitement de lesions cutanees
EP1572091A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1606418A4 (fr) Methodes de diagnostic et de traitement de l'epilepsie
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
ZA200604365B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1483407A4 (fr) Methodes therapeutiques et diagnostiques
EP1684795A4 (fr) Procedes et agents pour le traitement du cancer
GB0221712D0 (en) Methods of treatment
EP1567863A4 (fr) Procedes de therapie et de diagnostic
AU2002303430A8 (en) Compositions and methods for the diagnosis and treatment of tumor